Systematic Evaluation Of The Efficacy And Safety Of Compound Xueshuantong Combined With Cacium Dobesilate For The Oral Treatment Of Non-Proliferative Diabetic Retinopathy

Objective:To investigate the clinical efficacy and safety of compound xueshuantong co mbined with calcium dobesilate in the treatment of diabetic retinopathy,and to provide evidence-based medical evidence for clinical prac-tice.Methods:Reasonable search terms were set according to the purpose of the study,and the published academic papers in China Academic Journal Full Text Database(CNKI),Chinese Science and Technology Journal Database(VIP),Wanfang Database(Wangfang Data),China Biomedical Literature Database,and Pub Med database were searched by computer.The search period was from the establishment of the database to October 2022.A total of 28 randomized controlled trials including 3290 subjects were included in the study,including 1652 cases in the experimental group.There were 1638 cases in the control group.Rev Man 5.4 software was applied to analyze and process the data.Primary outcome indicators: total effective rate,visual acuity,macular thickness,angioma volume,visual field gray value,and hemorrhagic spot area.Secondary outcome indicators: total blood viscosity(high cut),total blood viscosity(low cut),serum inflammatory factor level,recurrence rate.Safety indicators: adverse reactions.Results:1.In the treatment of non-proliferative diabetic retinopathy with compound cxueshuantong combined with calcium dobesilate,the total clinical efficiency of the test group was better than that of the control group: OR=3.41,95%CI[2.78,4.19],Z=11.71,P<0.00001(P<0.05).2.Compound xueshuantong combined with calcium dobesilate for non-proliferative diabetic retinopathy had no significant difference between the test group and the control group in improving visual acuity,MD=-0.02,95% CI[-0.13,0.08],Z=0.42,P=0.68.3.The treatment of non-proliferative diabetic retinopathy with compound xueshuantong combined with calcium dobesilate was superior to the control group in reducing the area of hemorrhagic spots,MD=-0.76,95% CI[-0.85,-0.68],Z=17.90,P<0.00001(P<0.05).4.The treatment of non-proliferative diabetic retinopathy with compound xueshuantong combined with calcium dobesilate was superior to the control group in reducing the volume of angioma,MD=-3.25,95% CI[-3.79,-2.71],Z=11.83,P<0.00001(P<0.05).5.Compound xueshuantong combined with calcium dobesilate acid in calcium for non-proliferative diabetic retinopathy in reducing macular thic-kness,MD=-60.50,95% CI [-67.95,-53.06],Z=15.92,P<0.00001(P<0.05,Z=15.92,P<0.00001(P<0.05),the test group was superior to the control group.6.The treatment of non-proliferative diabetic retinopathy with compound xueshuantong combined with calcium dobesilate was superior to the control group in reducing the gray value of visual field,MD=-0.88,95% CI[-0.96,-0.80],Z=21.67,P<0.00001(P<0.05).7.The treatment of non-proliferative diabetic retinopathy with compound xueshuantong combined with calcium dobesilate was superior to the control group in reducing the level of vascular endothelial growth factor:(MD=-16.93,95% CI[-18.98,-14.88],Z=16.19,P<0.00001(P<0.05)).8.The treatment of non-proliferative diabetic retinopathy with compound xueshuantong combined with calcium dobesilate was superior to the control group in reducing serum insulin-like growth factor 1: MD=-32.98,95%CI[-36.38,-29.57],Z=18.98,P<0.00001(P<0.05).9.The treatment of non-proliferative diabetic retinopathy with compound xueshuantong combined with calcium dobesilate was superior to the control group in reducing hypersensitive C-reactive protein: MD=-1.95,95% CI[-2.52,-1.38],Z=6.70,P<0.00001(P<0.05).10.The treatment of non-proliferative diabetic retinopathy with compound xueshuantong combined with calcium dobesilate was superior to the control group in reducing whole blood viscosity(high cut): MD=-1.29,95% CI[-1.69,-0.89],Z=6.27,P<0.00001(P<0.05).11.The treatment of non-proliferative diabetic retinopathy with compound xueshuantong combined with calcium dobesilate was superior to the control group in reducing whole blood viscosity(low cut): MD=-1.38,95% CI[-2.05,-0.71],Z=4.04,P<0.0001(P<0.05).12.Compound xueshuantong combined with calcium dobesilate for non-proliferative diabetic retinopathy in reducing adverse effects: OR=0.69,95% CI[0.25,1.90],Z=0.71,P=0.48,no significant difference between the test group and the control group.13.Compound xueshuantong combined with calcium dobesilate for non-proliferative diabetic retinopathy was superior to the control group in reducing the recurrence rate: OR=0.13,95% CI[0.04,0.39],Z=3.65,P=0.0003.Conclusion:1.The oral treatment of non-proliferative diabetic retinopathy with com-pound xueshuantong and calcium dobesilate was superior to calcium dobesilate alone in terms of total clinical efficiency.2.Oral treatment of non-proliferative diabetic retinopathy with compound xueshuantong combined with calcium dobesilate was better than calcium dobesilate alone in reducing the area of hemorrh-agic spots,reducing the volume of hemangioma,reducing the thickn-ess of macula,improving the gray value of visual field,reducing the level of serum inflammatory factors and improving the blood rheology index.3.The oral treatment of non-proliferative diabetic retinopathy with compound xueshuantong and calcium dobesilate was comparable to calcium dobesilate alone in terms of visual acuity and adverse effects.4.The combination of compound xueshuantong and calcium dobesilate has good efficacy and safety in the treatment of non-prolifera-tive diabetic retinopathy.